The purpose of this study was to evaluate the incidence and extent of tumour cell contamination in bone marrow specimens and stem cell collections from 34 breast cancer patients undergoing high-dose therapy as adjuvant treatment, and to determine the prognostic significance for the clinical outcome. Tumour cell contamination was evaluated by flow cytometry using a double-colour test and an anti-Pan cytokeratin (CK) antibody. Two out of 34 (6%) baseline bone marrow specimens, none of seven marrow harvests and nine out of 32 aphereses (28%) mobilised from seven out of 27 patients (26%) contained CK+ cells. Tumour contamination was more frequent in patients with 10 or more involved lymph nodes and in those who received a shorter course of adjuvant chemotherapy before mobilisation. At a median follow-up of 43 months, 24 patients are in complete remission, whereas 10 patients experienced recurrence. Out of the 10 patients who relapsed, five (50%) had CK+ peripheral blood stem cell (PBSC) collections, whereas disease recurrence was seen in only two out of 24 (8%) patients who received CKÀ products (P ¼ 0.02). Moreover, CK+ PBSC collections were associated with a significantly shorter event-free survival and overall survival. CK+ collection is an unfavourable prognostic factor for patients treated with high-dose therapy. Whether the negative impact on clinical outcome depends on reinfusion of tumour cells or whether it simply indicates a larger disease extension is still unclear. 
Summary:
The purpose of this study was to evaluate the incidence and extent of tumour cell contamination in bone marrow specimens and stem cell collections from 34 breast cancer patients undergoing high-dose therapy as adjuvant treatment, and to determine the prognostic significance for the clinical outcome. Tumour cell contamination was evaluated by flow cytometry using a double-colour test and an anti-Pan cytokeratin (CK) antibody. Two out of 34 (6%) baseline bone marrow specimens, none of seven marrow harvests and nine out of 32 aphereses (28%) mobilised from seven out of 27 patients (26%) contained CK+ cells. Tumour contamination was more frequent in patients with 10 or more involved lymph nodes and in those who received a shorter course of adjuvant chemotherapy before mobilisation. At a median follow-up of 43 months, 24 patients are in complete remission, whereas 10 patients experienced recurrence. Out of the 10 patients who relapsed, five (50%) had CK+ peripheral blood stem cell (PBSC) collections, whereas disease recurrence was seen in only two out of 24 (8%) patients who received CKÀ products (P ¼ 0.02). Moreover, CK+ PBSC collections were associated with a significantly shorter event-free survival and overall survival. CK+ collection is an unfavourable prognostic factor for patients treated with high-dose therapy. In nonmetastatic disease, relapse rate is correlated with the number of lymph nodes involved. A recently published 20-year follow-up analysis 2 of a major adjuvant chemotherapy trial reported a 37% long-term progression-free survival among women with 1-3 involved axillary lymph nodes, a 26% progression-free survival among women with 4-10 involved axillary lymph nodes and no progression-free survivors among women with more than 10 involved lymph nodes.
In the last decade, the use of high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been evaluated as adjuvant treatment in high-risk patients. A few randomised phase III studies performed in the late 1990s [3] [4] [5] [6] reported no significant advantage in event-free survival (EFS) and overall survival (OS) for high-dose treatment in comparison with conventional-dose adjuvant chemotherapy, thus reducing the interest of oncologists in this procedure. However, more and better designed studies are still necessary to definitively answer the question of whether ASCT can improve quantity and quality of life, 7 and to identify clinical and biological prognostic factors for the patients who really could benefit from ASCT.
Since the presence of epithelial cells in the bone marrow (BM) appears to be an unfavourable prognostic factor for breast cancer patients treated with conventional-dose drugs, [8] [9] [10] [11] [12] [13] and this has been proposed to be included in the TNM classification as an independent indicator of poor outcome, 14 it is legitimate to investigate the possible role of tumour contamination of stem cell transplant products in disease recurrence after ASCT.
We evaluated the incidence of epithelial cell contamination in baseline BM specimens and in stem cell collections, by flow cytometry assay and with six different anticytokeratin (CK) monoclonal antibodies (MoAb), in 34 stage II and III breast cancer patients and correlated these data with the clinical outcome after adjuvant high-dose chemotherapy with stem cell rescue.
Patients and methods

Patient population
Between June 1994 and January 1998, 34 women with highrisk breast cancer and involvement of more than four axillary lymph nodes were enrolled in a programme of high-dose chemotherapy with peripheral blood stem cell (PBSC) support. Clinical features of the patients are summarised in Table 1 . All patients had histologically proven resectable invasive breast cancer (30 ductal, four lobular). Median age was 48 years (range, 30-56). Extensive staging was conducted, consisting of chest X-ray, thorax and abdominal CT scan, bone scan, BM biopsy and aspirate. All patients signed an informed consent.
In total, 22 patients (64%) had stage II disease, seven (21%) had stage IIIA and five (15%) had stage IIIB disease. The median number of involved lymph nodes was 9 (range, 4-28).
After surgery (mastectomy for 28 women and quadrantectomy for six), adjuvant treatment was chosen according to the number of axillary lymph nodes involved. A total of 20 patients with four to nine positive lymph nodes received four to six cycles of conventional chemotherapy including fluorouracil 500 mg/m 2 , epirubicin 75 mg/m 2 and cyclophosphamide 500 mg/m 2 (FEC) every 28 days.
Seven of these patients underwent marrow harvesting and 13 PBSC collection with one to three leukaphereses. Both groups of patients were mobilised with G-CSF 10 mg/ kg/day s.c. for 4 days and then treated with high-dose chemotherapy consisting of cyclophosphamide 50 mg/kg for 4 days and thiotepa 250 mg/m 2 .
The remaining 14 patients with 10 or more involved lymph nodes received a high-dose sequential chemotherapy programme according to the protocol designed by Gianni et al. Local radiation was given to all the patients who had received conservative surgery. Tamoxifen was administered for 5 years to the patients with positive oestrogen receptors.
Specimen preparation and evaluation
A search for tumour cell contamination was performed in all patients. BM biopses were analysed by histology and immunohistochemistry using a monoclonal antibreast cancer cell antibody (CAM 5.2), and marrow aspirates were analysed by flow-cytometry using a double-colour test. A 100-ml aliquot of each sample was simultaneously incubated with 10 ml of the PE-anti-CD45 antibody (BD, Milan, Italy) and with 5 ml of the FICT-Pan CR antibody Apheresis products were analysed in the same way as described for BM specimens. In four patients, leukaphereses containing X7 Â 10 6 /kg CD34+ cells and contaminated with CK+ cells were processed to select positively CD34+ cells, using an avidin-biotin immunoaffinity device (CEPRATE, CellPro). The median yield of the selection procedure was 65% (50-93%) and the median percentage of CD34 positivity in the final product was 85% (55-92%).
Statistical methods
Data are expressed as mean7s.d. or median and range for continuous variables and as a percentage for categorical variables. Distribution of continuous variables and categorical variables between the two groups of patients was compared using the Students t-test and the w 2 test, respectively.
EFS and OS were estimated with the Kaplan-Meier method. EFS was calculated from the day of PBSC transplantation until the date of last follow-up or event (death or relapse). OS was calculated from surgery to the last follow-up or death.
EFS and OS probability in the two groups of patients were compared with the log-rank test. 
Tumour contamination data
At diagnosis, BM histology and immunohistochemistry did not detect micrometastases in any patient. Flow cytometry on marrow specimens identified CK+ cells in two out 34 patients (6%) at a percentage of 0.035 and 0.01, respectively, whereas all the seven marrow harvests were CKÀ after FEC cycles and G-CSF administration.
Nine out of 32 aphereses (28%), mobilised from seven out of 27 patients (26%) (two after G-CSF only and five after cyclophosphamide plus G-CSF), contained CK+ cells. Samples of the leukapheresis products contained a median percentage of 0.15 (range, 0.10-0.33) CK+ cells, which is a median number of 6.6 Â 10 5 CK+ cells/kg. CK+ cells were detected in two out of 20 (10%) patients with four to nine positive lymph nodes, who were treated with FEC and in five out of 14 patients (36%) with involvement of more than 10 lymph nodes, who received the sequential protocol (P ¼ 0.06). Moreover, no significant association was found between mobilisation of breast tumour cells and other clinical features at diagnosis, such as tumour size, oestrogen receptor status, prior surgery and source of stem cells.
In four patients, leukapheresis products with a total median number of 7 Â 10 
Clinical outcome data
The median patient follow-up starting from the date of transplantation was 43 months (range, 12-76). Five varicella-zoster infections, two bacterial pneumonias, one mycotic otitis and one cervical carcinoma were observed during the follow-up. Haematologic engraftment was stable in all patients, but five developed persistent grade I neutropenia or grade I thrombocytopenia. To date, 24 patients are in complete remission, whereas 10 patients experienced a relapse at a median of 13 months after ASCT (range, 5-42). Nine out of the 10 relapsed patients died of tumour recurrence. Sites of progression were lungs in three patients, bones in two, bone marrow plus bone in another one, multiple sites including bone, liver, chest wall and central nervous system in the remaining four patients.
We evaluated the incidence of several variables such as clinical features at diagnosis and type of treatment in two groups of patients with different outcomes, those who relapsed and those who were still in clinical remission, and we identified that only CK+ collections were associated with a significant increase in tumour recurrence (Table 3) . In fact, out of the 10 patients who relapsed, five (50%) had CK+ PBSC collections, whereas disease recurrence was seen in only two out of 24 (8%) patients who received CKÀ products (P ¼ 0.02).
CD34+ selection was applied in four CK+ patients: two of them relapsed at 12 and 42 months after transplantation, respectively, whereas the remaining two patients were still in remission.
EFS and OS of the whole patient population are shown in Figure 1 . We analysed the association between EFS (or OS) and clinical features at disease diagnosis (listed in Table 3 ), and Figure 2 shows the significant correlation between CK+ collections and shorter EFS.
Discussion
Tumour contamination has been detected in 4-82% of BM specimens and leukapheresis products of patients with Tumour cell contamination of the graft and recurrence F Patriarca et al breast cancer. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] This large variability is because of the different MoAb used, the different sensitivity of the techniques, the heterogeneous composition of patients series, commonly including metastatic as well as nonmetastatic cases, and the different number of BM samples examined.
The presence of contaminating tumour cells in leukapheresis products has been commonly reported to be lower in comparison with BM baseline evaluations. In a few recent large studies with a better selection of patients and the exclusion of those who had overt metastatic disease, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] tumour contamination ranged from 4 to 7% of specimens examined. G-CSF alone resulted in a higher frequency of harvests containing occult tumour cells than chemotherapy plus G-CSF. 31 Moreover, the number of chemotherapy cycles administered before stem cell collection also appears to be important, with a reduction in contamination after the second cycle compared to the first one. 31 In our study, all patients had negative BM biopsies on histology and immunohistochemistry. After flow cytometry assay, only two out of 34 (6%) patients had baseline marrow specimens containing CK+ cells, but seven out of 27 (26%), including the two patients with positive BM, mobilised tumour cells in the peripheral blood. The frequency of tumour cell contamination was higher in the Tumour cell contamination of the graft and recurrence F Patriarca et al patients treated with the sequential protocol than in those receiving four FEC cycles. A first explanation is that the former had more lymph-node involvement and consequently more disseminated disease. In fact, the two positive baseline BM specimens belonged to this group. Another hypothesis is that the patients receiving the sequential protocol underwent mobilisation just after surgery and cyclophosphamide, whereas the other patients received four to six cycles of adjuvant therapy before stem cell collection, thus suggesting a possible role of adjuvant chemotherapy as in vivo purging. A few studies have correlated the frequency of leukaphereses contamination with the clinical outcome. 16, 18, 32 Moreover, two reports observed a trend towards a shorter relapse-free survival in patients transplanted with CK+ collections, 15, 17 whereas one study reached negative conclusions. 32 It should be emphasised that all of these studies had a median follow-up after transplantation shorter than 2 years, which is inadequate for drawing any conclusions in the setting of adjuvant therapy in breast cancer. However, all these studies reported a high frequency (40-57%) of tumour cell contamination in stem cell collections because of the inclusion of patients with metastatic disease or positive BM histology.
In our series of patients which excluded metastatic or micrometastatic cases, collection and reinfusion of CK+ cells was associated with a significantly shorter EFS and OS.
Other prognostic factors at diagnosis, such as lymphnode involvement and receptor status, did not appear to affect clinical outcome after high-dose treatment. This lack of correlation might be because of the different adjuvant treatments used in the two groups of patients, who were stratified at diagnosis on the basis of disease extent, or it might be related to the small number of patients.
The biologic significance of tumour cells contaminating PBSC preparations is a matter of debate. Although a few studies have reported that CK+ cells detected in BM or PBSC specimens could grow colonies in vitro, 19, 27 other mechanisms can be advocated to explain the role of the contaminating CK+ cells in the leukapheresis products. Circulating tumour cells might primarily reflect advanced stage disease and, after reinfusion they might influence long-term prognosis less than the underlying disease. Moreover, small amounts of tumour cells below a threshold value might be eliminated by the immune system of the patient.
Purging techniques were applied to reduce the number of CK+ cells contaminating the leukaphereses. CD34+ selection allowed a tumour cell depletion ranging from 0.7 to 4 logs according to the different studies, [33] [34] [35] [36] [37] but epithelial components were still detectable using immunocytochemical and PCR techniques. [32] [33] CD34+ selection allowed efficient haematopoietic reconstitution in patients receiving high-dose therapy, [33] [34] [35] [36] but conclusive data on clinical outcome are still lacking. In our study and in that of Vannucchi et al, 16 CD34+ selection did not appear to change the negative effect of CK+ cell contamination on the clinical outcome.
In conclusion, our study demonstrates that CK+ cell contamination of BM and leukaphereses was 6 and 28% in stage II and stage III breast cancer patients treated with adjuvant high-dose therapy. Since patients reinfused with CK+ cells had a significantly shorter EFS and OS than patients with CKÀ PBSC, tumour contamination of the graft appeared to be a powerful prognostic factor for the clinical outcome and should be taken into account in designing future protocols of high-dose therapy in breast cancer.
